ThromboGenics Stock Climbs on Microplasmin Phase III Data

Sheridan, Cormac
April 2010
BioWorld Today;4/21/2010, Vol. 21 Issue 76, p1
The article reports that shares in ThromboGenics NV reached its highest price at 18.80 euros following news that its lead drug candidate microplasmin posted good results in the first of two Phase III trials for treating symptomatic focal vitreomacular adhesion (VMA). The trial, which involved 326 patients, found that 27.7 percent of patients given a dose of the drug was cured after 28 days compared with only 13.2 percent in the placebo group. Stock price closed at 18.10 euros.


Related Articles

  • ThromboGenics Stock Up on Microplasmin Data.  // Bioworld Week;4/26/2010, Vol. 18 Issue 17, p4 

    The article reports that ThromboGenics NV's traded shares have reached an all-time high during its early trading on April 20, 2010 in view of the success of the Phase III trials of its lead drug microplasmin for the treatment of symptomatic focal vitreomacular adhesion (VMA).

  • NEJM Report Highlights Ocriplasmin Data.  // Review of Ophthalmology;Sep2012, Vol. 19 Issue 9, p6 

    The article reports on the Phase III clinical trials on ocriplasmin from ThromboGenics NV used in the treatment of vitreo-macular traction and macular holes. It says that the study involved patients with resolved vitreomacular adhesion (VMA). The study found that ocriplasmin has resolved VMA in...

  • THROMBOGENICS STARTS PHASE IIA OF MICROPLASMIN FOR STROKE.  // Worldwide Biotech;Nov2006, Vol. 18 Issue 11, p3 

    The article reports on a phase IIa trial initiated by ThromboGenics NV to evaluate microplasmin for the intra-arterial treatment of stroke. The study will enroll patients with acute vertebro-basilar artery occlusion. The purpose is to obtain initial safety information in the acute stroke patient...

  • CLINIC ROUNDUP.  // BioWorld Today;9/24/2009, Vol. 20 Issue 184, p2 

    This section offers news briefs concerning clinical trials. Alimera Sciences Inc. is conducting a pilot study of Iluvien, an intravitreal insert, to determine its efficacy against macular edema. Third and fourth batch of patients for the Phase II trial of TB-402 are being selected by BioInvent...

  • Clinic Roundup.  // BioWorld Today;8/23/2011, Vol. 22 Issue 163, p5 

    This section offers news briefs on drug clinical trials, which include the adult mesenchymal precursor cell product of Mesoblast Ltd. and the ocriplasmin trial for focal vitreomacular adhesion developed by ThromboGenics NV.

  • Turning a blind eye: the success of blinding reported in a random sample of randomised, placebo controlled trials. Fergusson, Dean; Glass, Kathleen Cranley; Shapiro, Stan; Waring, Duff // BMJ: British Medical Journal (International Edition);2/21/2004, Vol. 328 Issue 7437, p432 

    Abstract Objective: To examine the reporting and success of double blinding in a sample of randomised, placebo controlled trials from leading general medicine and psychiatry journals. Methods: Identification of placebo controlled, randomised controlled trials from prespecified general medical...

  • ATLAS TIMI 46: Rivaroxaban did not lower endpoint of death, MI, stroke, severe ischemia requiring revascularization.  // Cardiology Today;Dec2008, Vol. 11 Issue 12, p19 

    The article focuses on the results of the phase-2 ATLAS TIMI 46 trial participated by 3,491 patients who were receiving either aspirin alone or aspirin plus clopidogrel who then received rivaroxaban once daily or twice daily at the same dosing levels or placebo. Results showed that rivaroxaban...

  • Financings Roundup.  // BioWorld Today;9/21/2007, Vol. 18 Issue 184, p6 

    The article reports that ThromboGenics NV strengthened its cash position by &euro5.1 million through the exercise of 1.1 million pledges. It is stated that the company's number of outstanding shares increased to 25.5 million. ThromboGenics has various programs in the clinic which is in Phase II...

  • SURVIVAL ANALYSIS FROM SATRAPLATIN TRIAL DISAPPOINTING.  // Worldwide Biotech;Dec2007, Vol. 19 Issue 12, p8 

    The article reports that topline overall survival results for the double-blinded, randomized satraplatin Phase 3 registrational trial, the Satraplatin and Prednisone Against Refractory Cancer (SPARC) trial, has been announced by GPC Biotech AG and PharmionCorporation. The trial evaluated...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics